Tag Archives: CPK

Hot Warren Buffett Stocks To Buy For 2018

Investment company Warren Buffett buys Apple Inc, Bank of New York Mellon Corp, sells International Business Machines Corp, Twenty-First Century Fox Inc during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, Berkshire Hathaway. As of 2017-03-31, Berkshire Hathaway owns 46 stocks with a total value of $161.9 billion. These are the details of the buys and sells.

Added Positions: AAPL, BK, LUV, AAL, SIRI, LSXMA, Reduced Positions: IBM, DAL, WBC, Sold Out: FOXA,

For the details of Warren Buffett’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Warren+Buffett

These are the top 5 holdings of Warren BuffettThe Kraft Heinz Co (KHC) – 325,634,818 shares, 18.27% of the total portfolio. Wells Fargo & Co (WFC) – 479,704,270 shares, 16.49% of the total portfolio. Apple Inc (AAPL) – 129,357,106 shares, 11.48% of the total portfolio. Shares added by 125.52%Coca-Cola Co (KO) – 400,000,000 shares, 10.49% of the total portfolio. American Express Co (AXP) – 151,610,700 shares, 7.41% of the total portfolio. Added: Apple Inc (AAPL)

Warren Buffett added to the holdings in Apple Inc by 125.52%. The purchase prices were between $115.82 and $144.12, with an estimated average price of $131.33. The stock is now traded at around $153.99. The impact to the portfolio due to this purchase was 6.39%. The holdings were 129,357,106 shares as of 2017-03-31.

Hot Warren Buffett Stocks To Buy For 2018: American Assets Trust, Inc.(AAT)

Advisors’ Opinion:

  • [By Markus Aarnio]

    Owens Realty Mortgage’s competitors include American Assets Trust (AAT), Alexandria Real Estate Equities (ARE) and Boston Properties (BXP). American Assets Trust has seen five insider buy transactions and four insider sell transactions this year. American Assets Trust has a dividend yield of 2.78%. Alexandria Real Estate Equities has seen 14 insider sell transactions this year. Alexandria Real Estate Equities has a dividend yield of 4.10%. Boston Properties has seen one insider buy transaction and four insider sell transactions this year. Boston Properties has a dividend yield of 2.43%.

Hot Warren Buffett Stocks To Buy For 2018: Deer Valley Corporation (DVLY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Deer Valley (OTCPK:DVLY)

    This company manufactures factory-made homes which are marketed to 14 states in the US. After the financial crisis it has been able to pick up its operations and continue to create sustainable free cash flow and increasing profits. It might be that another similar shock to housing is not necessarily around the corner and therefore they could sustain this in the foreseeable future.

Hot Warren Buffett Stocks To Buy For 2018: Chesapeake Utilities Corporation(CPK)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Tuesday, utilities shares slipped by just 0.5 percent. Meanwhile, top gainers in the sector included Pampa Energia S.A. (ADR) (NYSE: PAM), up 2 percent, and Chesapeake Utilities Corporation (NYSE: CPK) up 3 percent.

Top 10 Medical Stocks To Invest In Right Now

Thesis: The threat to enforce federal marijuana laws might backfire by pushing Congress to legalize marijuana on the federal level. While in the short term, marijuana related stocks might suffer, if legislation is passed and signed into law, it would not only ease fears, but also make it more likely that more states will follow along with the pot legalization trend. This will have a long term positive effect on marijuana stocks.

The Threat

Right now, even though it flies in the face of reality and evidence, marijuana is listed as a schedule one drug: a drug with high potential for abuse, no currently accepted medical treatment use in the U.S., and lack of accepted safety for use of the drug or substance under medical supervision.

President Trump has threatened to increase enforcement of federal cannabis laws. One might think that this will have a negative impact on marijuana and marijuana related stocks like Aurora Cannabis (OTCQB:ACBFF), General Cannabis (OTCQB:CANN), Americann (OTCQX:ACAN), and MassRoots (OTCQB:MSRT), and if implemented it probably would be devastating, both to publicly traded marijuana companies, and to local companies in regions that have legalized pot.

Top 10 Medical Stocks To Invest In Right Now: iShares Mortgage Real Estate Capped (REM)

Advisors’ Opinion:

  • [By Donald van Deventer]

    The latest implied forward rate forecast from Kamakura Corporation shows projected 10-year U.S. Treasury yields differing -0.07% to 0.03% from last week while fixed rate mortgage yields varied by -0.01% to 0.08%. Mortgage yields, determined by the Monday through Wednesday weekly survey of the Federal Home Loan Mortgage Corporation, lag Treasury movements simply because of the 3-day yield calculation used in the Primary Mortgage Market Survey. The 10-year U.S. Treasury yield is projected to rise from 2.92% at Thursday’s close (down 0.06% from last week) to 3.374% (down 0.06% from last week) in one year. The 10-year U.S. Treasury yield in ten years is forecast to reach 4.639%, 1 basis point lower than last week. The 15-year fixed rate mortgage rate is forecast to rise from the effective yield of 3.69% on Thursday (down 0.001% from last week) to 4.222% (down 0.006% from last week) in one year and 6.29% in 10 years, up 0.038% from last week. We explain the background for these calculations in the rest of this note, along with some mortgage servicing rights metrics. The forecast allows investors in exchange traded U.S. Treasury funds (TLT) (TBT), total return bond funds (BOND), municipal bonds (NUV) and exchange traded mortgage funds (REM) to assess likely total returns over the next 120 months. Treasury-related exchange traded funds affected by the forward rates include:

Top 10 Medical Stocks To Invest In Right Now: Callon Petroleum Company(CPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

Top 10 Medical Stocks To Invest In Right Now: Bayer Aktiengesellschaft (BAYRY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    This type of spin-off is not uncommon among German companies, as they streamline their portfolios to focus on the where they have more competitive advantages in the long term. For instance, in the recent past, Siemens (OTCPK:SIEGY) has split out Osram (OTC:OSAGY) and Bayer (OTCPK:BAYRY) has performed the spin-off of Covestro (OTCPK:CVXTY), something that Rheinmetall is likely to do in the near future because its auto unit has reached peak margins, and therefore this is the best time to spin-off the business.

  • [By SEEKINGALPHA.COM]

    The Regeneron press release in November for its Q3 2017 financial and operating results reaffirmed Eylea’s full year 2017 U.S. net product sales growth of approximately 10% over 2016, which could be about $1 billion. From our model, we see the Q4 total revenues for Eylea, excluding sales outside the United States from Regeneron’s collaborative partner Bayer AG (OTCPK:BAYRY), of $1.2 billion, or a 17% increase year-on-year. REGN stock has a forward P/E ratio of 21.83 as of December 8, 2017, while the current trailing P/E is 34.57.

  • [By SEEKINGALPHA.COM]

    Fertilizers are only one input when it comes to farming, the equipment business has suffered, and seed suppliers are certainly concerned. Perhaps that is why another merger occurred last week between Monsanto (NYSE:MON) and Bayer (OTCPK:BAYRY). Bayer AG agreed to buy the U.S. seed manufacturer for $128 per share or approximately $47 billion creating a mammoth company with a combined value of almost $134.5 billion. The $128 per share price works out to a valuation of around 16 times earnings, which is cheap in a market where the average of S&P 500 stocks is trading at over 26.5 times earnings. However, the weakness in the agricultural sector caused disappointing earnings for Monsanto in the third quarter and a downbeat outlook for the future caused MON to accept Bayer’s bid. Bayer bought Monsanto at a low price, lowering the risk of the transaction for the German health care and agricultural giant.

  • [By Todd Campbell]

    Nektar Therapeutics is working with Bayer AG (NASDAQOTH:BAYRY) on an inhaledversion of Amikacin, an anti-bacterial that if successful in trials could be used alongside standard of care to treat gram-negative pneumonia in intubated and mechanically ventilated patients. If it’s eventually approved in the U.S., Nektar Therapeutics will receive a flat 30% royalty on sales. It’s also working with Bayer on an inhaled powder formulation of Cipro that could be used to treat chronic lung infections in cystic fibrosis patients. Top-line phase 3 results on both drugs should be available this year.

  • [By SEEKINGALPHA.COM]

    As the graphic below shows, ImmunoGen’s product pipeline is potentially significant. Furthermore, it is impressive to see the involvement and partnerships in these early stage compounds by some of the world’s leading pharmaceutical and biotech companies. This includes firms like Amgen (NASDAQ:AMGN), Roche (OTCQX:RHHBY), Bayer (OTCPK:BAYRY), Sanofi (NYSE:SNY), Eli Lilly (NYSE:LLY), and Novartis (NYSE:NVS).

Top 10 Medical Stocks To Invest In Right Now: WPP plc(WPPGY)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    WPP plc (WPPGY) — Most of WPP’s public websites were rendered inaccessible after the world’s biggest advertising group said its IT systems were the focus of a suspected cyberattack. Shares traded down almost 1% in early afternoon.

Top 10 Medical Stocks To Invest In Right Now: Entercom Communications Corporation(ETM)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap radio broadcasting stock Entercom Communications Corp (NYSE: ETM), a potential peer of Emmis Communications Corporation (NASDAQ: EMMS), Saga Communications (NYSEAMERICAN: SGA) and troubled Cumulus Media (NASDAQ: CMLS), is the tenth most shorted stock on the NYSE with short interest of 45.06% according to Highshortnterest.com.

Top 10 Medical Stocks To Invest In Right Now: GlaxoSmithKline PLC(GSK)

Advisors’ Opinion:

  • [By Todd Campbell]

    Also, like in hepatitis C, competitors are attempting to win away market share. For example,ViiV Healthcare, a joint venture spearheaded by GlaxoSmithKline(NYSE:GSK), is actively pursuing new HIV therapies that could make it more difficult for Gilead Sciences to maintain its market share dominance. In December, ViiV announced that a single tablet, two-drug combination that includes Johnson & Johnson’s Edurant met its primary endpoint in phase 3 studies. A filing for FDA approval is slated for this year.

  • [By WWW.MONEYSHOW.COM]

    Donald Trump understands how regulation harms both businesses and consumers, discouraging innovation and raising costs. In a recent news conference, he pledged to “cut regulations by 75%, maybe more.”  This is good news indeed for drug companies like GlaxoSmithKline (GSK).

  • [By Paul Ausick]

    GlaxoSmithKline plc (NYSE: GSK) dropped about 1% Wednesday to post a new 52-week low of $34.52 after closing at $34.86 on Tuesday. The stock’s 52-week high is $44.54. Volume of around 4.8 million was about equal to the daily average. The company’s HIV drug is being challenged by a potentially better drug from competitor Gilead Sciences.

  • [By Keith Speights]

    Gilead’s primary rival in the HIV market is Viiv Healthcare, which is majority-owned byGlaxoSmithKline (NYSE:GSK).The company recently announced positive results from a late-stage clinical study of its HIV drug Tivicay combined with Johnson & Johnson’s Edurant.

  • [By Sean Williams]

    Third, in late March, Mylan announced that the Food and Drug Administration had rejected its application to market a generic version of GlaxoSmithKline’s (NYSE:GSK) blockbuster asthma and COPD inhalable drug, Advair. GlaxoSmithKline’s Advair lost patent protection more than six years ago, but only within the past couple of years did the FDA lay out a course for generic drug producers to follow in order to get a generic version of the drug approved. Meanwhile, Glaxo still enjoys blockbuster sales of Advair as generic versions of the drug have yet to hit the market.

Top 10 Medical Stocks To Invest In Right Now: Royal Gold Inc.(RGLD)

Advisors’ Opinion:

  • [By Scott Levine]

    Climbing nearly 6% through January, the price of gold outpaced the meager gain — approximately 1% — of the S&P 500. Unsurprisingly, many of the market’s largest gold stocks enjoyed double-digit gains, including AngloGold Ashanti (NYSE:AU), Barrick Gold (NYSE:ABX), IAMGOLD (NYSE:IAG), and Royal Gold (NASDAQ:RGLD).

  • [By Alex McGuire]

    This list ranks gold dividend stocks in the mining sector by dividend yield. And it also includes one of our top gold stock recommendations of 2017…

    Gold Dividend Stock Share Price Year-to-Date Performance Dividend Yield (as of June 30)
    DRDGOLD Ltd. (NYSE ADR: DRD) $3.19 -39.7% 10.24%
    Sibanye Gold Ltd. (NYSE ADR: SBGL) $4.70 -33.4% 5.98%
    Harmony Gold Mining Co. (NYSE ADR: HMY) $1.62 -26.7% 4.56%
    Gold Fields Limited (NYSE ADR: GFI) $3.41 +13.3% 2.73%
    Randgold Resources Ltd. (Nasdaq ADR: GOLD) $87.68 +14.9% 1.89%
    Franco Nevada Corp. (NYSE: FNV) $72.39 +21.1% 1.27%
    Royal Gold Inc. (Nasdaq: RGLD) $76.85 +21.3% 1.25%
    Eldorado Gold Corp. (NYSE: EGO) $2.58 -19.9% 1.16%
    Barrick Gold Corp. (NYSE: ABX) $15.90 -0.5% 0.75%
    Goldcorp Inc. (NYSE: GG) $13.02 -4.4% 0.62%

    Six of the 10 gold stocks listed above have posted negative returns so far in 2017. The main reason behind their losses has to do with gold price volatility.

Top 10 Medical Stocks To Invest In Right Now: Chesapeake Utilities Corporation(CPK)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Tuesday, utilities shares slipped by just 0.5 percent. Meanwhile, top gainers in the sector included Pampa Energia S.A. (ADR) (NYSE: PAM), up 2 percent, and Chesapeake Utilities Corporation (NYSE: CPK) up 3 percent.

Top 10 Medical Stocks To Invest In Right Now: BanColombia S.A.(CIB)

Advisors’ Opinion:

  • [By Matt Smith]

    Bancolombia appears attractively priced
    Another Colombian company that appears under-valued is the Andean country’s largest commercial bank Bancolombia (NYSE: CIB  ) . For the year-to-date Bancolombia’s share price fell 17% because of a weak second quarter bottom-line. This decline was primarily caused by the bank’s net income plunging by 41% year-over-year because of mark-to-market losses caused by the value lost in the bank’s securities portfolio.

  • [By Javier Hasse]

    Analysts at Credit Suisse downgraded shares of Bancolombia SA (ADR) (NYSE: CIB) from Outperform to Neutral, while boosting their price target from $38 to $40.

  • [By Lisa Levin]

    Foreign Regional Banks: This industry declined 2 percent by 11:00 am with Bancolombia SA (ADR) (NYSE: CIB) moving down 3.7 percent. Bancolombia’s PEG ratio is 4.51.

Top 10 Medical Stocks To Invest In Right Now: Hudson Pacific Properties, Inc.(HPP)

Advisors’ Opinion:

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on Friday.

    Douglas Dynamics Inc (NYSE: PLOW) – $0.2350 dividend, 2.9183 percent yield
    Tiffany & Co. (NYSE: TIF) – $0.4500 dividend, 2.6758 percent yield
    PulteGroup, Inc. (NYSE: PHM) – $0.0900 dividend, 1.7078 percent yield
    Leidos Holdings, Inc. (NYSE: LDOS) – $0.3200 dividend, 3.0851 percent yield
    Tupperware Brands Corporation (NYSE: TUP) – $0.6800 dividend, 4.1756 percent yield
    Hudson Pacific Properties Inc (NYSE: HPP) – $0.2000 dividend, 2.36

Top 5 High Tech Stocks To Watch For 2018

With the S&P 500 hitting another new high yesterday, UBS strategistJulian Emanuel and team wonder if buyback activity is signalling a market top:

Spencer Platt/Getty Images

On one hand, many would argue that the emphasis on share repurchases is merely a sign of the times the US economy continues to grow (albeit slowly) while corporates enjoy ample balance sheet flexibility in an entirely unprecedented ultralow interest rate environment characterized by the Fed’s ongoing reluctance to raise rates as much of the world’s government debt has moved to negative yields…

On the other hand, buyback activity near all-time highs could be considered a potential sign that the current Bull Market is approaching its peak. While there is a plausible argument supporting greater share repurchases return of excess cash in the absence of viable alternative investments firms have historically exhibited poor timing. Management tends to repurchase shares in bull markets when profits are high and balance sheets are flush with cash, while cutting back during recessions (precisely the time they should be buying over the long term).

Top 5 High Tech Stocks To Watch For 2018: Celanese Corporation(CE)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Time To Favor Optionality: Most macro data are similar to, or better than, when the merger was announced. As a result, the same returns have been obtainable, with significantly less stress, simply through owning 3M (MMM) or a basket of chemical companies that approximate the Dow-DuPont portfolio. Relative to the chemical sector, performance has been average, leverage appears reasonable but near-term FCF less-than compelling partly due to new capacity ramping. With the merger likely to close in the near-term (90% chance, in our view), we believe Dow-DuPont will have an opportunity to show how scale creates optionality. The overhaul at Celanese (CE) over the past few years shows the way.

Top 5 High Tech Stocks To Watch For 2018: Aurora Cannabis Inc. (ACBFF)

Advisors’ Opinion:

  • [By Sean Williams]

    This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.

    GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%

    As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!

  • [By Javier Hasse]

    While biotechs like GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) and Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) only lost 0.45 percent and 0.36 percent respectively, other companies experienced a large tumble. CANOPY GROWTH CORP COM NPV (OTC: TWMJF) lost 4.71 percent, AURORA CANNABIS IN COM NPV (OTC: ACBFF) slipped 2.93 percent, APHRIA INC COM NPV (OTC: APHQF) dropped 1.01 percent, and MassRoots Inc (OTC: MSRT) plummeted an astounding 9.00 percent.

  • [By Javier Hasse]

    Also quite recently, Benzinga asked Alan Brochstein, founding partner at New Cannabis Ventures and founder at 420 Investor, about plays in the marijuana industry against such an uncertain backdrop. The expert mentioned a few Canadian Licensed Producers, including AURORA CANNABIS IN COM NPV (OTC: ACBFF), APHRIA INC NPV (OTC: APHQF), METTRUM HEALTH COR COM NPV (OTC: MQTRF), ORGANIGRAM HLDGS I COM NPV (OTC: OGRMF), SUPREME PHARMACEUT COM NPV (OTC: SPRWF) and CANOPY GROWTH CORP COM NPV (OTC: TWMJF), as well as “the only” biotech stock in the space, GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH).

  • [By Keith Speights]

    As increasingly more marijuana growers entered the market and more states allowed residents to legally grow marijuana, cannabis prices dropped throughout 2016. Wholesale marijuana prices late in the year were roughly half the levels of 12 months earlier. Will this trend continue — and possibly hurt leading marijuana stocks including Aphria (NASDAQOTH:APHQF),Aurora Cannabis (NASDAQOTH:ACBFF), Medical Marijuana,Inc.(NASDAQOTH:MJNA), and even GW Pharmaceuticals (NASDAQ:GWPH) in the process?

  • [By SEEKINGALPHA.COM]

    This article is for those who are hopeful of the long-term view and want to get in ahead of time. This article will compare the three front-runners of the Canadian cannabis industry, Canopy Growth Corp. (OTCPK:TWMJF), Aphria (NYSE:APH), and Aurora (OTCQX:ACBFF). Although these companies will soon have to prove themselves in a new environment, there is plenty to study right now. We will be comparing revenue growth, production capacity, valuations, and then making financial projections. The result will be a recommendation of Aurora followed by Canopy. Again this article is meant to compare competitors. The industry has the potential to be a 22.6B industry but the thesis for investing in Canadian cannabis is a separate topic and I encourage you to consider the risks.

Top 5 High Tech Stocks To Watch For 2018: DXP Enterprises Inc.(DXPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of DXP Enterprises Inc (NASDAQ: DXPE) were down 17 percent to $24.00. DXP Enterprises reported preliminary revenue of $228 million to $231 million for the third quarter.

  • [By Lisa Levin]

    Shares of DXP Enterprises Inc (NASDAQ: DXPE) got a boost, shooting up 22 percent to $40.27 after the company posted upbeat quarterly results.

    Nature's Sunshine Prod. (NASDAQ: NATR) shares were also up, gaining 28 percent to $11.35 as the company disclosed that it has received its direct selling license in China.

Top 5 High Tech Stocks To Watch For 2018: Chesapeake Utilities Corporation(CPK)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Tuesday, utilities shares slipped by just 0.5 percent. Meanwhile, top gainers in the sector included Pampa Energia S.A. (ADR) (NYSE: PAM), up 2 percent, and Chesapeake Utilities Corporation (NYSE: CPK) up 3 percent.

Top 5 High Tech Stocks To Watch For 2018: Great Plains Energy Inc(GXP)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Westar Energy stock declined 8% after regulators at the Kansas Corporation Commissions blocked the sale of Westar to Great Plains Energy (NYSE:GXP). The $12.2 billion merger would have joined utilities in Kansas and Missouri. Great Plains had argued that the combination would produce nearly $2 billion in efficiency gains in the next 10 years, but regulators instead sided with those who had argued that the deal was too rich and would have required rate increases sooner rather than later. Great Plains stock was hardly affected at all by the decision, leading many to conclude that Westar had a lot more to lose from the deal falling through then Great Plains had to gain from a successful merger.